dyslipidemia
Conditions
Interventions
Switch from standard statins (pravastatin, fluvastatin, simbastain) to rosuvastatin (5mg) 1 TAB/day for 12 weeks
Treat with Ezetimib (10mg) 1 TAB/day for 12 weeks and standard statins (pravastatin, fl
Sponsors
Department of Medicine II, Hokkaido University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Dyslipidemic patients whose serum LDL-C levels are more than 140 mg/dL despite medication of any dose of statins ( pravastatin, fluvastatin, or simbastain). Written informed consent was given by patients. The study protocol was approved by the Ethics Committee of Hokkaido University.
Exclusion criteria
Exclusion criteria: 1. Patients who has been treated by any strong statins (rosvastatin, atrovastatin, and pitavastatin) or ezetimib. 2. Patients who are suffered from severe liver, kidney, or heart diseases. 3. Patients who are pregnant, lactating, or could be pregnant 4. Patients with the history of allergy for study drugs. 5. Patients treated with cyclosporin. 6. Patients were deemed inappropriate for this study as the doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| comparison of changes of LDL-C levels between the groups in rosuvastatin monotherapy and ezetimib/standard statin combination therapy | — |
Countries
Japan
Contacts
Public ContactSo Nagai, MD PhD
Hokkaido University Hospital Department of Medicine II
Outcome results
None listed